Developer docs
API playgroundTry for free, no card

Search company profiles

Aclaris Therapeutics

Full company profile

uuid0000ra6

Namestring
Aclaris Therapeutics
Legal namestring
Aclaris Therapeutics, Inc.
Websiteurl
aclaristx.com
Company typeenum
Public
Founded yearint
2012
Descriptiontext

Aclaris Therapeutics is a clinical-stage biopharmaceutical company headquartered in Wayne, Pennsylvania, that develops small molecule and biologic drug candidates for immuno-inflammatory diseases spanning dermatology, respiratory, and autoimmune indications. The company is publicly traded on NASDAQ under the ticker ACRS and was founded in 2012. Aclaris operates a proprietary drug discovery platform called KINect®, which combines a chemical library of several hundred kinase inhibitor compounds with structure-based drug design and custom kinase assays to identify candidates targeting non-catalytic cysteine residues across more than 300 kinases. Its clinical pipeline includes bosakitug (ATI-045, an anti-TSLP monoclonal antibody), ATI-052 (a TSLP/IL-4 bispecific antibody), ATI-2138 and ATI-9494 (oral ITK/JAK3 and ITK/TXK inhibitors), and lepzacotinib (ATI-1777, a topical JAK1/JAK3 inhibitor); it also holds worldwide rights to BSI-082 (anti-BH3 antibody) under a licensing agreement with Biosion. All candidates are investigational and none have received regulatory approval.

Aclaris is pre-revenue from a product perspective and funds its operations primarily through public and private equity financings — most recently a $59.8 million Q1 2026 raise that brought cash to $190.8 million and extended stated runway into 2028. Its primary commercial pathway is out-licensing clinical assets to large pharmaceutical and biotechnology partners, supplemented by contract research services provided through wholly-owned subsidiary Confluence Discovery Technologies, Inc., a CRO based in St. Louis. Confluence generates the entirety of the company's reported quarterly revenue (approximately $1.3 million per quarter). Management is led by co-founder Neal Walker (CEO and Chair), with a substantially refreshed executive team including Hugh Davis (President and COO), Jesse Hall (CMO), and Roland Kolbeck (CSO), appointed between late 2024 and mid-2025. Aclaris was added to the Nasdaq Biotechnology Index in December 2025.

The company's revenue model is a hybrid of clinical development (out-licensing milestones and royalties) and services (Confluence CRO). Its customer base consists of unnamed pharmaceutical and biotech companies utilizing Confluence's discovery services, and prospective licensing partners for its clinical-stage assets. As a public, development-stage company with no approved products, Aclaris is structurally unprofitable, with net losses widening to $19.8 million in Q1 2026 versus $15.1 million in Q1 2025.

Short descriptiontext

Aclaris Therapeutics is a publicly traded clinical-stage biopharmaceutical company that develops small molecule and biologic drug candidates for immuno-inflammatory diseases using its proprietary KINect® kinase inhibitor discovery platform, targeting licensing partnerships with large pharma and operating a CRO subsidiary.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersWayne, United States
HQ citystring
Wayne
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
immuno-inflammatory therapeutics, kinase inhibitor discovery, clinical-stage biopharmaceuticals, dermatology drug development, contract research services
Industry1 code
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Clinical-Stage Biopharmaceutical Drug Development
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Equity Financings
TypeOne Time License
Description

Aclaris is a pre-revenue clinical-stage company. It funds operations through public equity offerings and private placements. The company completed a significant public equity financing in early 2026.

aclaristx.com
2Strategic Licensing Partnerships
TypeLicensing Royalties
Description

The company seeks to out-license its investigational drug candidates to pharmaceutical and biotechnology partners for development and commercialization, generating potential milestone payments and royalties.

aclaristx.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Aclaris Therapeutics is a clinical-stage biopharmaceutical company developing small molecule and biologic drug candidates for immuno-inflammatory diseases, supported by its proprietary KINect® kinase inhibitor discovery platform. The company has no approved commercial products; its candidates (e.g., bosakitug/ATI-045, ATI-2138, ATI-052, lepzacotinib/ATI-1777) are available only through clinical trials and are intended to be out-licensed to larger pharmaceutical and biotech partners for further development and commercialization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Multiple investigational new drug (IND) applications filed and cleared by FDA
+1 more record
Product overview1 text field

Aclaris Therapeutics is a biopharmaceutical company developing a portfolio of investigational drug candidates for immuno-inflammatory diseases. The company's pipeline includes biologic products (bosakitug, ATI-052) and small molecule inhibitors (ATI-2138, ATI-9494, lepzacotinib) targeting dermatologic, respiratory, and immunologic conditions. The proprietary KINect® platform supports small molecule drug discovery through kinase inhibitor chemistry and structure-based design. All products are investigational and not yet approved by regulatory authorities.

Product and service7 records
1Bosakitug (ATI-045)
CategoryClinical Development Compound
Description

An investigational novel humanized anti-TSLP monoclonal antibody that binds to human thymic stromal lymphopoietin (TSLP) with high affinity and long residence time, blocking its interaction with the receptor complex to disrupt signal transduction. Potential indications include severe asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, and COPD.

2ATI-2138
CategoryClinical Development Compound
Description

An investigational oral covalent inhibitor targeting ITK (Interleukin-2-Inducible T Cell Kinase) and JAK3 for T cell-mediated autoimmune diseases. Dual inhibition is intended to produce additive or synergistic anti-inflammatory activity in autoimmune and inflammatory diseases.

3ATI-052
CategoryClinical Development Compound
Description

An investigational humanized bispecific antibody that blocks both TSLP receptor signal transduction and IL-4 receptor activation to inhibit central proinflammatory pathways. Engineered to bind more tightly to FcRn for extended half-life; potential indications include respiratory and dermatology conditions.

4ATI-9494
CategoryPreclinical Development Compound
Description

A highly potent and selective preclinical investigational oral agent acting as a dual inhibitor of ITK and TXK/RLK Tec family kinases expressed in T cells. Demonstrates potent blockade of Th1 and Th2 responses with prolonged half-life, potentially enabling once-daily administration.

5Lepzacotinib (ATI-1777)
CategoryClinical Development Compound
Description

An investigational soft topical JAK1/JAK3 inhibitor designed for topical application that is active in skin but rapidly metabolized when entering the bloodstream to minimize systemic exposure. Potential therapeutic targets include atopic dermatitis and other dermatologic conditions.

6KINect® Platform
CategoryDrug Discovery Platform
Description

A proprietary drug discovery technology platform that accelerates identification of drug candidates through a combination of a proprietary chemical library of kinase inhibitors, structure-based drug design expertise, and custom kinase assays. Central to the platform is a novel chemical library of several hundred compounds targeting non-catalytic cysteine residues of over 300 kinases.

7Confluence Discovery Technologies Contract Research Services
CategoryContract Research Services
Description

Full-service drug discovery and early development contract research services provided by Aclaris's wholly-owned subsidiary Confluence Discovery Technologies. Capabilities include cell and molecular biology, biochemistry, enzymology, biomarker development, immunology and inflammation, in vivo efficacy models, bioanalytical, computational and medicinal chemistry, and kinase inhibitor screening for pharmaceutical and biotechnology clients.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Biosion
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Aclaris entered into a global licensing and collaboration agreement with Biosion for BSI-082, an anti-BH3 antibody. The partnership grants Aclaris rights to develop and commercialize BSI-082 globally in exchange for an upfront payment and potential development, regulatory, and commercial milestones. Hugh Davis, Aclaris's Chief Business Officer, led the deal at his prior firm before joining Aclaris.

clinicaltrialsarena.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage dermatology specialty pharma developing small molecule and biologic therapies for immuno-inflammatory skin conditions such as atopic dermatitis and psoriasis — directly comparable to Aclaris's dermatology-focused pipeline including lepzacotinib.

TypeDirect peer
Description

Clinical-stage immunology biotech developing antibody therapeutics for inflammatory and autoimmune diseases, sharing Aclaris's immuno-inflammatory focus and biologics/small molecule strategy.

TypeDirect peer
Description

Clinical-stage immunology company developing biologics for inflammatory diseases including dermatologic conditions, with a similar small/mid-cap public structure and out-licensing optionality.

4Dice Therapeutics
TypeDirect peer
Description

Clinical-stage biotech developing oral small molecules against protein-protein interactions for immunology indications; comparable to Aclaris's kinase-inhibitor approach in immuno-inflammatory disease.

TypeDirect peer
Description

Clinical-stage immunology company developing small molecule and oral biologic therapies for autoimmune and inflammatory diseases, with a comparable pipeline and partnership-oriented business model.

TypeDirect peer
Description

Clinical-stage immunology biotech developing small molecules for inflammatory diseases, including kinase-targeted approaches that overlap with Aclaris's KINect® discovery platform thesis.

7Evolus
TypeRegional player
Description

Specialty aesthetics/dermatology company focused on immuno-inflammatory indications; relevant comparable for Aclaris's dermatology positioning and specialty-pharma commercial playbook.

TypeBroad incumbent
Description

Large biopharma with deep immuno-inflammatory franchise (Humira, Rinvoq, Skyrizi) and active in-licensing of clinical-stage assets — a natural potential partner/competitor shaping Aclaris's licensing economics.

TypeBroad incumbent
Description

Major biopharma with strong inflammation/autoimmune portfolio (Tezspire via AstraZeneca partnership, Otezla); a likely counterparty in any TSLP-targeted out-licensing from Aclaris.

TypeBroad incumbent
Description

Large biopharma with established respiratory and immunology franchise (Tezspire, Fasenra) and historical kinase-inhibitor expertise via MedImmune — natural strategic acquirer or partner for Aclaris's pipeline.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aclaris Therapeutics

Clinical-Stage Biopharmaceutical Drug Developmentaclaristx.com

Aclaris Therapeutics is a publicly traded clinical-stage biopharmaceutical company that develops small molecule and biologic drug candidates for immuno-inflammatory diseases using its proprietary KINect® kinase inhibitor discovery platform, targeting licensing partnerships with large pharma and operating a CRO subsidiary.

What Aclaris Therapeutics does

Aclaris Therapeutics is a clinical-stage biopharmaceutical company headquartered in Wayne, Pennsylvania, that develops small molecule and biologic drug candidates for immuno-inflammatory diseases spanning dermatology, respiratory, and autoimmune indications. The company is publicly traded on NASDAQ under the ticker ACRS and was founded in 2012. Aclaris operates a proprietary drug discovery platform called KINect®, which combines a chemical library of several hundred kinase inhibitor compounds with structure-based drug design and custom kinase assays to identify candidates targeting non-catalytic cysteine residues across more than 300 kinases. Its clinical pipeline includes bosakitug (ATI-045, an anti-TSLP monoclonal antibody), ATI-052 (a TSLP/IL-4 bispecific antibody), ATI-2138 and ATI-9494 (oral ITK/JAK3 and ITK/TXK inhibitors), and lepzacotinib (ATI-1777, a topical JAK1/JAK3 inhibitor); it also holds worldwide rights to BSI-082 (anti-BH3 antibody) under a licensing agreement with Biosion. All candidates are investigational and none have received regulatory approval.

Aclaris is pre-revenue from a product perspective and funds its operations primarily through public and private equity financings — most recently a $59.8 million Q1 2026 raise that brought cash to $190.8 million and extended stated runway into 2028. Its primary commercial pathway is out-licensing clinical assets to large pharmaceutical and biotechnology partners, supplemented by contract research services provided through wholly-owned subsidiary Confluence Discovery Technologies, Inc., a CRO based in St. Louis. Confluence generates the entirety of the company's reported quarterly revenue (approximately $1.3 million per quarter). Management is led by co-founder Neal Walker (CEO and Chair), with a substantially refreshed executive team including Hugh Davis (President and COO), Jesse Hall (CMO), and Roland Kolbeck (CSO), appointed between late 2024 and mid-2025. Aclaris was added to the Nasdaq Biotechnology Index in December 2025.

The company's revenue model is a hybrid of clinical development (out-licensing milestones and royalties) and services (Confluence CRO). Its customer base consists of unnamed pharmaceutical and biotech companies utilizing Confluence's discovery services, and prospective licensing partners for its clinical-stage assets. As a public, development-stage company with no approved products, Aclaris is structurally unprofitable, with net losses widening to $19.8 million in Q1 2026 versus $15.1 million in Q1 2025.

Aclaris Therapeutics firmographics

Firmographics
Name
Aclaris Therapeutics
Legal name
Aclaris Therapeutics, Inc.
Website
https://aclaristx.com
Company type
Public
Founded year
2012
Operating status
Operating
Headcount range
51–100 employees
Short description
Aclaris Therapeutics is a publicly traded clinical-stage biopharmaceutical company that develops small molecule and biologic drug candidates for immuno-inflammatory diseases using its proprietary KINect® kinase inhibitor discovery platform, targeting licensing partnerships with large pharma and operating a CRO subsidiary.
Ownership category
akta.pro rank

Aclaris Therapeutics industry classification

Industry
Product category
Clinical-Stage Biopharmaceutical Drug Development
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Immuno-inflammatory therapeutics
  • Kinase inhibitor discovery
  • Clinical-stage biopharmaceuticals
  • Dermatology drug development
  • Contract research services

Where Aclaris Therapeutics is headquartered

Location

Headquarters

HQ city
Wayne
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Aclaris Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Equity Financings: Aclaris is a pre-revenue clinical-stage company. It funds operations through public equity offerings and private placements. The company completed a significant public equity financing in early 2026.
  2. Strategic Licensing Partnerships: The company seeks to out-license its investigational drug candidates to pharmaceutical and biotechnology partners for development and commercialization, generating potential milestone payments and royalties.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Aclaris Therapeutics product offering

Product offering

Core offering

Aclaris Therapeutics is a clinical-stage biopharmaceutical company developing small molecule and biologic drug candidates for immuno-inflammatory diseases, supported by its proprietary KINect® kinase inhibitor discovery platform. The company has no approved commercial products; its candidates (e.g., bosakitug/ATI-045, ATI-2138, ATI-052, lepzacotinib/ATI-1777) are available only through clinical trials and are intended to be out-licensed to larger pharmaceutical and biotech partners for further development and commercialization.

Product overview

Aclaris Therapeutics is a biopharmaceutical company developing a portfolio of investigational drug candidates for immuno-inflammatory diseases. The company's pipeline includes biologic products (bosakitug, ATI-052) and small molecule inhibitors (ATI-2138, ATI-9494, lepzacotinib) targeting dermatologic, respiratory, and immunologic conditions. The proprietary KINect® platform supports small molecule drug discovery through kinase inhibitor chemistry and structure-based design. All products are investigational and not yet approved by regulatory authorities.

Differentiator

Problem solved

Functional benefit

Products and services

  • Bosakitug (ATI-045) An investigational novel humanized anti-TSLP monoclonal antibody that binds to human thymic stromal lymphopoietin (TSLP) with high affinity and long residence time, blocking its interaction with the receptor complex to disrupt signal transduction. Potential indications include severe asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, and COPD.
  • ATI-2138 An investigational oral covalent inhibitor targeting ITK (Interleukin-2-Inducible T Cell Kinase) and JAK3 for T cell-mediated autoimmune diseases. Dual inhibition is intended to produce additive or synergistic anti-inflammatory activity in autoimmune and inflammatory diseases.
  • ATI-052 An investigational humanized bispecific antibody that blocks both TSLP receptor signal transduction and IL-4 receptor activation to inhibit central proinflammatory pathways. Engineered to bind more tightly to FcRn for extended half-life; potential indications include respiratory and dermatology conditions.
  • ATI-9494 A highly potent and selective preclinical investigational oral agent acting as a dual inhibitor of ITK and TXK/RLK Tec family kinases expressed in T cells. Demonstrates potent blockade of Th1 and Th2 responses with prolonged half-life, potentially enabling once-daily administration.
  • Lepzacotinib (ATI-1777) An investigational soft topical JAK1/JAK3 inhibitor designed for topical application that is active in skin but rapidly metabolized when entering the bloodstream to minimize systemic exposure. Potential therapeutic targets include atopic dermatitis and other dermatologic conditions.
  • KINect® Platform A proprietary drug discovery technology platform that accelerates identification of drug candidates through a combination of a proprietary chemical library of kinase inhibitors, structure-based drug design expertise, and custom kinase assays. Central to the platform is a novel chemical library of several hundred compounds targeting non-catalytic cysteine residues of over 300 kinases.
  • Confluence Discovery Technologies Contract Research Services Full-service drug discovery and early development contract research services provided by Aclaris's wholly-owned subsidiary Confluence Discovery Technologies. Capabilities include cell and molecular biology, biochemistry, enzymology, biomarker development, immunology and inflammation, in vivo efficacy models, bioanalytical, computational and medicinal chemistry, and kinase inhibitor screening for pharmaceutical and biotechnology clients.

Quantifiable outcome

  • Multiple investigational new drug (IND) applications filed and cleared by FDA
  • +1 more outcomes

Companies that use Aclaris Therapeutics

Customer profile

Segments3 records

Ideal customer profiles3 records

Aclaris Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Aclaris Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • BiosioncoreStrategic or Co-development PartnerAclaris entered into a global licensing and collaboration agreement with Biosion for BSI-082, an anti-BH3 antibody. The partnership grants Aclaris rights to develop and commercialize BSI-082 globally in exchange for an upfront payment and potential development, regulatory, and commercial milestones. Hugh Davis, Aclaris's Chief Business Officer, led the deal at his prior firm before joining Aclaris.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Aclaris Therapeutics competitors and assessment

Company assessment

Direct peers

  • Arcutis Biotherapeutics: Clinical-stage dermatology specialty pharma developing small molecule and biologic therapies for immuno-inflammatory skin conditions such as atopic dermatitis and psoriasis — directly comparable to Aclaris's dermatology-focused pipeline including lepzacotinib.
  • AnaptysBio: Clinical-stage immunology biotech developing antibody therapeutics for inflammatory and autoimmune diseases, sharing Aclaris's immuno-inflammatory focus and biologics/small molecule strategy.
  • MoonLake Immunotherapeutics: Clinical-stage immunology company developing biologics for inflammatory diseases including dermatologic conditions, with a similar small/mid-cap public structure and out-licensing optionality.
  • Dice Therapeutics: Clinical-stage biotech developing oral small molecules against protein-protein interactions for immunology indications; comparable to Aclaris's kinase-inhibitor approach in immuno-inflammatory disease.
  • Ventyx Biosciences: Clinical-stage immunology company developing small molecule and oral biologic therapies for autoimmune and inflammatory diseases, with a comparable pipeline and partnership-oriented business model.
  • RAPT Therapeutics: Clinical-stage immunology biotech developing small molecules for inflammatory diseases, including kinase-targeted approaches that overlap with Aclaris's KINect® discovery platform thesis.

Regional players

  • Evolus: Specialty aesthetics/dermatology company focused on immuno-inflammatory indications; relevant comparable for Aclaris's dermatology positioning and specialty-pharma commercial playbook.

Broad incumbents

  • AbbVie: Large biopharma with deep immuno-inflammatory franchise (Humira, Rinvoq, Skyrizi) and active in-licensing of clinical-stage assets — a natural potential partner/competitor shaping Aclaris's licensing economics.
  • Amgen: Major biopharma with strong inflammation/autoimmune portfolio (Tezspire via AstraZeneca partnership, Otezla); a likely counterparty in any TSLP-targeted out-licensing from Aclaris.
  • AstraZeneca / MedImmune: Large biopharma with established respiratory and immunology franchise (Tezspire, Fasenra) and historical kinase-inhibitor expertise via MedImmune — natural strategic acquirer or partner for Aclaris's pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Aclaris Therapeutics social profiles

Digital presence

Aclaris Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aclaris Therapeutics leadership team

Management profile

Number of profiles

Profiles13 records

Aclaris Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Aclaris Therapeutics funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aclaris Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aclaris Therapeutics

What does Aclaris Therapeutics do?

Aclaris Therapeutics is a clinical-stage biopharmaceutical company developing small molecule and biologic drug candidates for immuno-inflammatory diseases, supported by its proprietary KINect® kinase inhibitor discovery platform. The company has no approved commercial products; its candidates (e.g., bosakitug/ATI-045, ATI-2138, ATI-052, lepzacotinib/ATI-1777) are available only through clinical trials and are intended to be out-licensed to larger pharmaceutical and biotech partners for further development and commercialization.

Is Aclaris Therapeutics a public or private company?

Aclaris Therapeutics is a public company. It is classified as public and is currently operating.

When was Aclaris Therapeutics founded?

Aclaris Therapeutics was founded in 2012. It employs 51 to 100 people.

Where is Aclaris Therapeutics based?

Aclaris Therapeutics is headquartered in Wayne, United States, in the North America region.

How does Aclaris Therapeutics make money?

Two revenue lines are on record. Equity Financings are the primary driver. The others are strategic Licensing Partnerships.

Who are Aclaris Therapeutics's main competitors?

Direct peers on record are Arcutis Biotherapeutics, AnaptysBio, MoonLake Immunotherapeutics, Dice Therapeutics, Ventyx Biosciences and RAPT Therapeutics. Evolus is listed as a regional player. Broad incumbents are AbbVie, Amgen and AstraZeneca / MedImmune.

Does Aclaris Therapeutics have an API?

No public API is recorded for Aclaris Therapeutics.

What industry is Aclaris Therapeutics in?

Aclaris Therapeutics's product category is Clinical-Stage Biopharmaceutical Drug Development. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Defense WorldAclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Has Consensus Price Target of $10.67Aclaris Therapeutics shares opened at $3.50 with a consensus price target of $10.67 from nine analysts. The company reported a loss of $0.12 per share, beating the consensus of $0.16, with revenue of $1.48 million. Analysts expect a loss of $0.56 per share for the current fiscal year.American Banking and Market NewsAclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Rated “Buy” by Wall Street BrokeragesAclaris Therapeutics received an average "Buy" rating from nine analysts, with a 1-year price objective of $10.67. The stock opened at $3.50, and the company reported Q3 EPS of -$0.12, beating estimates of -$0.16, with revenue of $1.48 million.Defense WorldAclaris Therapeutics (NASDAQ:ACRS) Downgraded by Wedbush to NeutralWedbush downgraded Aclaris Therapeutics from Outperform to Neutral, cutting its price target to $3 from $8. The company reported Q3 EPS of -$0.12, beating estimates, but revenue of $1.48 million missed consensus. Institutional investors hold 98.34% of the stock.Investing.comAclaris stock falls after atopic dermatitis trial failsAclaris Therapeutics shares fell 6% after its Phase 2 ADMIRATION trial for atopic dermatitis failed to meet primary and secondary endpoints. The trial evaluated bosakitug, an anti-TSLP antibody, which showed target engagement but did not achieve efficacy. The company will continue development of oral kinase inhibitors and a bispecific antibody, and initiated a Phase 2b trial for lichen planus.BenzingaWhy is Aclaris Therapeutics Stock Trading Lower on Monday? - Aclaris Therapeutics (NASDAQ:ACRS)Aclaris Therapeutics shares fell 13.52% to $3.39 on Monday after its Phase 2 ADMIRATION trial of bosakitug missed primary and secondary endpoints in atopic dermatitis. The company launched a Phase 2b trial of modzatinib for lichen planus and plans to submit an IND for ATI-9494 this quarter.BenzingaAclaris Therapeutics, Summit Therapeutics And Other Big Stocks Moving Lower In Monday’s Pre-Market SessioU.S. stock futures fell Monday, with Nasdaq 100 futures down over 1%. Aclaris Therapeutics shares dropped 20.8% after its Phase 2 ADMIRATION trial missed endpoints, while Summit Therapeutics fell 17% after FDA approval concerns for ivonescimab. Other stocks declined on weak sales, Bitcoin drops, or prior declines.TradingViewAclaris Therapeutics Reports Phase 2 Bosakitug Miss and Advances Lichen Planus TrialAclaris Therapeutics reported that bosakitug missed primary and secondary endpoints in the Phase 2 ADMIRATION trial for atopic dermatitis, though the drug was well tolerated and showed target engagement. The company initiated a Phase 2b modzatinib trial in lichen planus, with OLP results expected in H2 2027, and plans to file an ATI-9494 IND in Q4 2026.FierceBiotechAclaris drops TSLP program from pipeline after flunking phase 2 eczema testAclaris Therapeutics removed bosakitug from its pipeline after a phase 2 trial in atopic dermatitis missed its primary endpoint. The Admiration trial of 110 patients showed no statistically significant improvement in EASI scores versus placebo at week 24, despite pharmacodynamic engagement. The company now focuses on its bispecific antibody ATI-052 and oral kinase inhibitors.TradingViewCanaccord Genuity maintains Aclaris Therapeutics at Buy, raises price target to $13 from $10Canaccord Genuity maintained Aclaris Therapeutics at Buy and raised its price target to $13 from $10, a 30% increase. The target implies a 227.5% upside from the Oct 30 close of $3.97.American Banking and Market NewsWedbush Issues Pessimistic Forecast for Aclaris Therapeutics (NASDAQ:ACRS) Stock PriceWedbush lowered its price target on Aclaris Therapeutics from $10 to $8, keeping an outperform rating. The stock opened at $3.99, with a consensus Buy rating and $11 target. The company reported Q2 EPS of -$0.15, beating estimates.